Serum proteomics analysis of lung transplant patients receiving different induction therapies
Our findings suggest alemtuzumab may have a stronger effect on circulating proteome. Further studies are warranted to elucidate the underlying mechanisms and explore potential clinical implications.
Authors
- H.O. Berezhinskiy (ORCID: https://orcid.org/0009-0009-6037-5617)
- Alberto Benazzo (ORCID: https://orcid.org/0000-0002-3549-4720)
- Thomas Mohr (ORCID: https://orcid.org/0000-0002-1933-847X)
- Markus Unterwurzacher
- Péter Jaksch (ORCID: https://orcid.org/0000-0003-4635-3242)
- Klaus Kratochwill (ORCID: https://orcid.org/0000-0003-0803-614X)
- Konrad Hoetzenecker
- S. Nasrollahi Shirazi (ORCID: https://orcid.org/0009-0005-8447-1444)
- Clemens Aigner (ORCID: https://orcid.org/0000-0002-7787-991X)
- Sophia Alemanno
Institutions
- Comprehensive Cancer Center Vienna (AT)
- Christian Doppler Laboratory for Thermoelectricity (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-28
- DOI
- https://doi.org/10.3389/fimmu.2025.1616781
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universität Wien
- Medizinische Universität Wien